This activity is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from Daiichi Sankyo and AstraZeneca.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

Faculty & Disclosures

Listen on the go

View and download resources from this activity to support your learning and share with colleagues

Download Slides
CORRECT!
Next Step
Faculty & Disclosures
Prof. Marina Garassino

The University of Chicago, Chicago, USA

Prof. Marina Garassino is a professor of medicine in the Department of Medicine, Section of Hematology-Oncology, at The University of Chicago in the USA. Before assuming this role, she served as chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori in Milan, Italy, until February 2021. In this capacity, she led the clinical and translational research strategy for advanced and locally advanced non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma and thymic malignancies. read more

Prof. Garassino earned her medical degree and further specialization in medical oncology from the University of Milan, graduating (110/110 cum laude) in 1995. She completed her training through an ESMO Clinical Fellowship at The Christie NHS Foundation Trust in Manchester, UK, in 2009.

As a medical oncologist, Prof. Garassino has focused her research on precision medicine and immuno-oncology, with an emphasis on developing new drugs, therapeutic strategies and biomarkers. She previously served as chair of TYME, the Italian research network for thymic malignancies, and has contributed to over 260 peer-reviewed publications, including first- and last-author papers in The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Annals of Oncology.

She has also delivered numerous presentations at major international conferences, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the European CanCer Organization (ECCO), the World Conference on Lung Cancer (WCLC) and the American Association for Cancer Research (AACR). Over the past 5 years, she has secured multiple research grants from organizations such as the Italian Medicines Agency (AIFA), AIRC Foundation for Cancer Research, ERA-NET TRANSCAN, The Guido Berlucchi Foundation, Horizon 2020 and industry-sponsored trials.

She has been an active member of the European Medicines Agency’s (EMA) Scientific Advisory Group (SAG) and has served on the ESMO Council as chair of National Societies. From 2011 to 2017, she was the ESMO Italian national representative and continues to contribute to several ESMO task forces, including the Public Policy Extended Committee, the Press Committee and Women for Oncology. Additionally, she has served as ASCO faculty for the Lung Cancer Track.

Prof. Garassino is also the founder and honorary president of Women for Oncology Italy.

Prof. Marina Garassino discloses: Speaker’s bureau and advisory panel fees from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IO Biotech, Janssen Pharmaceuticals, Merck & Co, Mirati Therapeutics, Natera, Novocure, Nuvation, Pfizer, Regeneron, Revolution Medicines, Roche and Takeda. Grant/research support from AIFA, AIRC, Horizon 2020, Italian MoH and TRANSCAN.
Prof. Jarushka Naidoo

Beaumont RCSI Cancer Centre, Dublin, Ireland

Prof. Jarushka Naidoo is a consultant medical oncologist at the Beaumont Hospital Dublin and a full professor at the Royal College of Surgeons in Ireland (RCSI). Before joining RCSI in late 2020, she was an assistant professor of medical oncology and a lung cancer specialist at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in the USA. She currently holds the position of adjunct assistant professor of oncology at Johns Hopkins University. She also serves as the national lung cancer lead for Cancer Trials Ireland. read more

Prof. Naidoo received her medical degree from Trinity College Dublin and completed her internal medicine and medical oncology training in Ireland. This was followed by an advanced medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York, USA, before joining the faculty at Johns Hopkins and then returning to Ireland.

Prof. Naidoo is an internationally recognized leader in immunotherapy for lung cancer, melanoma and immune-related toxicity. She contributes to several international guideline panels, including those for the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). She is an experienced clinical trialist, having developed and completed several investigator-initiated, industry-funded, and cooperative group clinical trials.

Prof. Naidoo has received numerous grants, including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), the Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2 programme. She is deeply committed to education and training in oncology and has mentored numerous early-career physicians, fellows and medical students, whose achievements include high-level publications and young investigator awards.

Prof. Jarushka Naidoo discloses: Advisory board or panel fees from AbbVie, Amgen, Arcus Biosciences, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Elevation Oncology, Mirati Therapeutics, Novartis, Oxford Therapeutics, Pfizer, Regeneron, Roche/Genentech, Summit Therapeutics, Takeda and Zymeworks. Grant/research support from Amgen, Arcus Biosciences, Bristol Myers Squibb, Daiichi Sankyo, Mirati Therapeutics, Novartis and Roche/Genentech.
Prof. David Planchard

Institut Gustave Roussy, Villejuif, France

Prof. David Planchard is a thoracic oncologist and head of the Thoracic Group at Institut Gustave Roussy (IGR) in Villejuif, France. With over 20 years of experience, his research has focused on immunotherapy, genomic analysis, biomarkers, and targeted treatments for lung cancer. He has been involved in more than 300 phase I, II and III clinical trials and has authored over 270 publications. Since 2020, he has been recognized as a Clarivate ‘Highly Cited Researcher’. read more

Prof. Planchard has been directly involved in clinical trial design, serving as the international coordinating investigator for multiple trials in the field of thoracic tumours to develop a long-term research strategy based on molecular screening.

He has contributed to the latest European recommendations for the management of metastatic non-small cell lung cancer (European Society for Medical Oncology [ESMO] guidelines) and is an active speaker at leading national and international conferences, including ESMO, the European Lung Cancer Congress (ELCC), the American Society of Clinical Oncology (ASCO) and the World Conference on Lung Cancer (WCLC).

Prof. David Planchard discloses: Advisory board or panel fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharmaceuticals, Merck, Mirati Therapeutics, Novartis, Pfizer, Pierre Fabre, Roche, Seagen and Takeda. Clinical trials research as principal or co-investigator (institutional financial interests) fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Janssen Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Novartis, Novocure, Pfizer, Pierre Fabre, Roche, Sanofi-Aventis, Seagen, Taiho Pharma and Takeda.
Back to Faculty
touchONCOLOGY touchONCOLOGY
Start activity
Videos Take CE/CME Test
Lung Cancer CE/CME accredited

touchSYMPOSIUM
An enduring activity from a live meeting, experts discuss pertinent data which could improve patient care and outcomes. Close

Navigating the clinical impact of TROP2-targeting in NSCLC

Faculty Featured
Learning Objectives

After watching this activity, participants should be better able to:

  • Assess the efficacy and safety profiles of TROP2 ADCs compared with standard treatments in NSCLC
  • Evaluate the utility of measuring TROP2 expression levels in NSCLC and the specific patient populations included in clinical trials to determine eligibility for TROP2-targeted therapies
  • Develop evidence-based management approaches for specific TROP2-targeted ADC toxicities in NSCLC
Overview

In this symposium, Prof. Marina Garassino, Prof. Jarushka Naidoo and Prof. David Planchard share their insights on TROP2-targeted ADCs in NSCLC. They discuss the latest clinical trial data; challenges in using TROP2 as a biomarker in practice; and the unique side-effect profiles of ADCs, offering practical strategies for toxicity management. read more

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

Target Audience

Oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurse specialists

USF Accreditation

Disclosures

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

Faculty

Prof. Marina Garassino discloses: Speaker’s bureau and advisory panel fees from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IO Biotech, Janssen Pharmaceuticals, Merck & Co, Mirati Therapeutics, Natera, Novocure, Nuvation, Pfizer, Regeneron, Revolution Medicines, Roche and Takeda. Grant/research support from AIFA, AIRC, Horizon 2020, Italian MoH and TRANSCAN.

Prof. Jarushka Naidoo discloses: Advisory board or panel fees from AbbVie, Amgen, Arcus Biosciences, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Elevation Oncology, Mirati Therapeutics, Novartis, Oxford Therapeutics, Pfizer, Regeneron, Roche/Genentech, Summit Therapeutics, Takeda and Zymeworks. Grant/research support from Amgen, Arcus Biosciences, Bristol Myers Squibb, Daiichi Sankyo, Mirati Therapeutics, Novartis and Roche/Genentech.

Prof. David Planchard discloses: Advisory board or panel fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharmaceuticals, Merck, Mirati Therapeutics, Novartis, Pfizer, Pierre Fabre, Roche, Seagen and Takeda. Clinical trials research as principal or co-investigator (institutional financial interests) fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Janssen Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Novartis, Novocure, Pfizer, Pierre Fabre, Roche, Sanofi-Aventis, Seagen, Taiho Pharma and Takeda.

Content Reviewer

Danielle Walker, DNP, APRN, AGNP-C, has no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Contributors

Kathy Day has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact cpdsupport@usf.edu 

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Advanced Practice Providers

Physician Assistants may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditsTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Date of original release: 31 March 2025. Date credits expire: 31 March 2026.

If you have any questions regarding credit, please contact cpdsupport@usf.edu

Nurses

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.25 contact hour(s) may be earned by learners who successfully complete this continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

Date of original release: 31 March 2025. Date credits expire: 31 March 2026.

If you have any questions regarding credit please contact cpdsupport@usf.edu

EBAC® Accreditation

touchIME is an EBAC® accredited provider since 2023.

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 70 minutes of effective education time.

The Accreditation Council for Continuing Medical Education (ACCME®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBAC®.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBAC® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.

Faculty Disclosure Statement / Conflict of Interest Policy

In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

Faculty

Prof. Marina Garassino discloses: Speaker’s bureau and advisory panel fees from AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IO Biotech, Janssen Pharmaceuticals, Merck & Co, Mirati Therapeutics, Natera, Novocure, Nuvation, Pfizer, Regeneron, Revolution Medicines, Roche and Takeda. Grant/research support from AIFA, AIRC, Horizon 2020, Italian MoH and TRANSCAN.

Prof. Jarushka Naidoo discloses: Advisory board or panel fees from AbbVie, Amgen, Arcus Biosciences, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Elevation Oncology, Mirati Therapeutics, Novartis, Oxford Therapeutics, Pfizer, Regeneron, Roche/Genentech, Summit Therapeutics, Takeda and Zymeworks. Grant/research support from Amgen, Arcus Biosciences, Bristol Myers Squibb, Daiichi Sankyo, Mirati Therapeutics, Novartis and Roche/Genentech.

Prof. David Planchard discloses: Advisory board or panel fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharmaceuticals, Merck, Mirati Therapeutics, Novartis, Pfizer, Pierre Fabre, Roche, Seagen and Takeda. Clinical trials research as principal or co-investigator (institutional financial interests) fees from AbbVie, ArriVent BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Janssen Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Novartis, Novocure, Pfizer, Pierre Fabre, Roche, Sanofi-Aventis, Seagen, Taiho Pharma and Takeda.

Requirements for Successful Completion

Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

Date of original release: 31 March 2025. Date credits expire: 31 March 2027.

Time to Complete: 70 minutes

If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org

Useful tips
  • Downloads including slides are available for this activity in the Toolkit

You may also be interested in...

Topics covered in this activity

Lung Cancer
REGISTER NOW FOR FREE ACCESS TO
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 8 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now

Journal articles and more to your inbox

Get the latest clinical insights from touchONCOLOGY

Sign me up!
This activity is funded by:

An independent medical education grant from Daiichi Sankyo and AstraZeneca.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF

USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

Date of original release: 31 May 2025. Date credits expire: 31 May 2026.

EBAC® 

touchIME is an EBAC® accredited provider since 2023.

In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

This content is intended for healthcare professionals outside the UK.

Claim Credit
touchSYMPOSIUM
Navigating the clinical impact of TROP2-targeting in NSCLC
1.25 CE/CME credit

You may also be interested in...

This activity is funded by:

An independent medical education grant from Daiichi Sankyo and AstraZeneca.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF

USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

Date of original release: 31 May 2025. Date credits expire: 31 May 2026.

EBAC® 

touchIME is an EBAC® accredited provider since 2023.

In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

This content is intended for healthcare professionals outside the UK.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup